695 0 Kommentare BioMarin Announces Prosensa Therapeutics B.V. Changes Name to BioMarin Nederland B.V.

SAN RAFAEL, Calif., April 28, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Prosensa Therapeutics B.V., a BioMarin company, changed its name to BioMarin Nederland B.V. This name change reflects the further integration of Prosensa into BioMarin.

BioMarin acquired Prosensa on Jan. 15, 2015. BioMarin maintains operations at the former Prosensa headquarters, based in Leiden, The Netherlands and has integrated personnel from that office into the company.

Long

85,97€

Basispreis

0,74

Ask

× 10,05

Hebel

Zum Produkt

Short

101,05€

Basispreis

1,06

Ask

× 7,02

Hebel

Zum Produkt

Präsentiert von

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

"We are pleased that the integration of Prosensa employees into the BioMarin family is going smoothly. We share a common purpose of delivering therapies that will make a meaningful difference to patients with rare genetic diseases," said Scott Clarke, Site Leader, BioMarin Nederland. "Together, we are working to bring treatments to boys with Duchenne muscular dystrophy."

About Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a severely debilitating childhood neuromuscular disease that affects up to 1 in 3,500 live male births. This rare disease is caused by mutations in the dystrophin gene, resulting in the absence or defect of the dystrophin protein. As a result, patients suffer from progressive loss of muscle strength, often rendering them wheelchair-bound before the age of 12. Respiratory and cardiac muscle can also be affected by the disease and most patients die in early adulthood due to respiratory and cardiac failure.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates.

For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

CONTACT: Investors:
         Traci McCarty
         BioMarin Pharmaceutical Inc.
         (415) 455-7558
         
         Media:
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BioMarin Pharmaceutical Inc. via Globenewswire

HUG#1915650